- Press Release -

Rockville, Md. The global peptide based hematological disorders therapeutics market is set to reach nearly US$ 530 Mn by 2022 on robust growth, according to Fact.MR. Rapidly evolving peptide manufacturing, from new synthesis methods to automated instruments that improve purification and cut waste, is lowering production costs and enabling longer, more complex peptide chains.

Ecallantide leads by drug, retail pharmacies carry the largest share, and North America, led by the United States, dominates demand.

Drugs, Channels and Regions

Ecallantide is the leading drug, reaching nearly US$ 120 Mn by 2022 at over a fifth of revenue and gaining share. On distribution, retail pharmacies hold more than a third of revenue and gain ground. North America reaches nearly US$ 220 Mn by 2022, with the United States alone accounting for about 88.6% of global revenue in 2017 and gaining further share.

Manufacturing Advances Drive Demand

The market runs on production technology. As manufacturers refine synthesis and purification, peptide therapeutics become more viable and affordable, though the difficulty of synthesising and purifying long peptides, compounded by more modifications and unnatural amino acids, keeps costs high and supply constrained.

Competitive Landscape

The report profiles the leading participants shaping the market, including Shire plc, with competition centred on advancing peptide drug development and manufacturing capability.

Reading the Market for Decisions

For drug makers, growth favours scalable manufacturing and expanded peptide portfolios. Investors get a small, specialised market with robust growth concentrated in the United States. Procurement and pharmacy teams can plan around ecallantide carrying volume, retail pharmacies leading distribution, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global peptide based hematological disorders therapeutics market for the 2017 to 2022 forecast period, with segmentation by drug, distribution channel and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the peptide based hematological disorders therapeutics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.